View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 8, 2022

Inspira signs distribution deal with Glo-Med for Hyla blood sensor in US

The HYLA blood sensor continuously measures important indicators, such as partial oxygen levels and carbon dioxide pressures.

Inspira Technologies has signed an exclusive summary distribution agreement with Glo-Med Networks.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

According to the terms of the agreement, Glo-Med Networks will distribute Inspira’s HYLA blood sensor device, as well as disposable units, in the US states of New Jersey, South Carolina, North Carlina, Florida, Texas and New York.

The HYLA non-invasive blood sensor provides quick, real-time and continuous vital blood monitoring without using actual blood samples from patients.

The device is designed to continuously measure many important indicators, including partial oxygen levels and carbon dioxide pressures, which are said to be accurate indicators of a patient’s health disorders and deterioration.

Inspira Technologies stated that real-time patient blood monitoring provides alerts for physicians that allow them to potentially save more lives.

The HYLA blood sensor is claimed to benefit patients undergoing intensive care unit (ICU) monitoring, extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, dialysis and cardiopulmonary bypass.

The distribution agreement, which is subject to the completion of product development and regulatory approvals, has an initial term of three years and will be followed by a more comprehensive deal.

Glo-Med has committed to purchasing 3,889 HYLA blood sensors and 264,873 disposable units for deployment at hospitals and medical centres.

Glo-Med CEO Matus Knoblich said: “I believe that this ground-breaking technology may dramatically reduce the need for actual blood sampling by the hospital staff.

“This could significantly reduce their workload while providing potentially critical information at a critical moment when a patient’s medical condition may suddenly deteriorate without warning.

“I strongly believe that this technology has the potential to eventually become a device for almost every patient in ICUs and other suitable clinical settings.”

The latest deal is Inspira’s second distribution agreement with Glo-Med. The first deal, for the distribution of the company’s ART system in the US, was signed in January.

Inspira noted that the HYLA blood sensor and ART system have not been tested or used in humans.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network